B
Live / Applied — First extension granted (statement of use) (as of 23 Oct 2025)
What this means for you
Not registered yet, but its 10 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98641751
- Mark type
- Design + words
- Filed
- 10 Jul 2024
- Published for opposition
- 11 Mar 2025
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 24 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Oct 2025 — SOU EXTENSION 1 GRANTED
- 23 Oct 2025 — SOU EXTENSION 1 FILED
- 23 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Mar 2025 — PUBLISHED FOR OPPOSITION
- 05 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Feb 2025 — ASSIGNED TO EXAMINER
- 31 Jan 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 31 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Jul 2024 — NEW APPLICATION ENTERED